Samuel Zinga Defends Thesis on Novel TB Drug Targets
Please join us in wishing Samuel Zinga the very best ahead of his thesis defense!
A graduate student in the Rubin Lab, Samuel is presenting his research, “Targeting the Clp Protease for Mycobacterial Drug Development,”on Friday March 20th.
Tuberculosis (TB) kills more people each year than any other infectious disease, and drug resistance rates continue to rise. There is an urgent need for new drugs to treat this ancient scourge. One strategy is to characterize and target essential processes in Mycobacterium tuberculosis, the bacterium that causes TB. Samuel’s work has shed new light on the Clp protease system as a promising novel drug target.
We are excited to celebrate this moment and cheer him on as he takes this next step in his scientific career!
